Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia.
For more information, please visit www.thereliefstudy.com or www.clinicaltrials.gov (NCT04172831).

Pipeline
: Scientific Presentations

Scientific Presentations

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*

Presented at the American Society of Microbiology (ASM) BioThreats Conference in Arlington, VA on January 29, 2020 Poster Session #2 - 4:15 pm.

Ryan Noyce, Landon Westfall, Siobhan Fogarty, Karen Gilbert, Onesmo Mpanju, Helen Stillwell, Jose Esparza, Fusataka Koide, David Evans, and Seth Lederman

Uploaded: Jan 29, 2020
Type: Pdf

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

Presented by Dr. Gregory Sullivan at the American College of Rheumatology in Atlanta, GA on November 10, 2019

Gregory Sullivan, R. Michael Gendreau, Judith Gendreau, Ashild Peters, Perry Peters, and Seth Lederman

Uploaded: Nov 20, 2019
Type: Pdf

Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP

Presented at the American Society of Clinical Psychopharmacology in Scottsdale, AZ on May 29, 2019 Poster Session I – Poster ID W29, 11:15 AM – 1 PM EDT, Palomino

Gregory Sullivan, Regina Kiu, Helen Stillwell, Bernd Meibohm, and Seth Lederman

Uploaded: May 29, 2019
Type: Pdf

Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

Presented at CNS Summit in Boca Raton, FL November 1-4, 2018; Poster 8A, Friday Nov. 2, 5:00-7:00 PM EDT, Reception and Poster Session, and abstract published in Innovations in Clinical Neuroscience, November-December 2018;15(11-12, suppl):S10.

Gregory Sullivan, MD, R Michael Gendreau, MD, PhD, Judy Gendreau, MD, Ashild Peters, RN, Perry Peters, Jean Engels, MS, Seth Lederman, MD

Uploaded: Nov 6, 2018
Type: Pdf

Differential Treatment Effects of a Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD

Presented at CNS Summit in Boca Raton, FL November 1-4, 2018; Poster 8A, Friday Nov. 2, 5:00-7:00 PM EDT, Reception and Poster Session, and abstract published in Innovations in Clinical Neuroscience, November-December 2018;15(11-12, suppl):S9.

Gregory M. Sullivan, Kimmons Wilson, R. Michael Gendreau, Judy Gendreau, Ashild Peters, Perry Peters, Amy Forst, Jean Engels, Seth Lederman

Uploaded: Nov 6, 2018
Type: Pdf

Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies

Presented at the 2018 Military Health System Research Symposium in Kissimmee, FL August 20 – 23

Poster Discussion Session: Innovations in PTSD Treatment Research

Gregory Sullivan, R Michael Gendreau, Judy Gendreau, Ashild Peters, Perry Peters, Amy Forst, Jean Engels, Seth Lederman

Uploaded: Aug 21, 2018
Type: Pdf

Including Suicidal Individuals in Treatment Trials: Treatment of Military-Related PTSD with TNX-102 SL, a Novel Sublingual Formulation of Cyclobenzaprine Hypothesized to Address PTSD through Improvement in Sleep Quality

Presented at the American Society of Clinical Psychopharmacology in Miami Beach, FL May 29 – June 1, 2018
ASCP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time

Seth Lederman, Gregory Sullivan, Judy Gendreau, Ashild Peters, Perry Peters,

Uploaded: May 31, 2018
Type: Pdf

Efficacy and Safety of a Low Dose, Bedtime, Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL#) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301)

Presented at the Military Health System Research Symposium (MHSRS) in Kissimmee, FL August 27-30; MHSRS-17-1626 Poster Session 2 - Poster #519, 10:00 AM - 4:30 PM EDT, Florida Exhibit Hall D-F

Gregory M. Sullivan, Helen Stillwell, Florence Porterfield, Judy Gendreau, R. Michael Gendreau, Ashild Peters, Perry Peters, Seth Lederman

Uploaded: Aug 29, 2017
Type: Pdf

Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response

Presented at the Military Health System Research Symposium (MHSRS) in Kissimmee, FL August 27-30; MHSRS-17-1685 Poster Session 2 - Poster #521, 10:00 AM - 4:30 PM EDT, Florida Exhibit Hall D-F

Gregory M. Sullivan, Helen Stillwell, Florence Porterfield, Judy Gendreau, R. Michael Gendreau, Ashild Peters, Perry Peters, Seth Lederman

Uploaded: Aug 29, 2017
Type: Pdf

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

Poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, FL on June 1, 2017

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Jean Engels, Perry Peters, Ashild Peters, Seth Lederman

Uploaded: Jun 1, 2017
Type: Pdf
1 | 2 | 3 | 4 Next >>